Macro Group Pharmaceutical S.A.E. (MCRO) Revenue

Revenue

EGP 526.01M

Fiscal year 2023

Revenue (also called sales or turnover) is the total income a company generates from its core business before any costs or expenses are deducted. For EGX-listed companies it is reported in the annual income statement in Egyptian pounds.

Revenue history

Fiscal yearRevenueYoY growth
2023526.01M-27.91%
2022729.61M22.78%
2021594.26M

All monetary figures in EGP. Source: Egyptian Exchange via TradingView; annual figures from company disclosures; updated weekly. Prices refresh every 15 minutes during EGX trading hours.